57 results
8-K
EX-10.1
SLNO
Soleno Therapeutics Inc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
Print name of Spouse
Signature of Spouse
(if the Warrant Shares are held in joint name or are community property)
B. THIS SECTION B
424B5
SLNO
Soleno Therapeutics Inc
29 Sep 23
Prospectus supplement for primary offering
4:51pm
of DCCR, if and when approved, by patients, the medical community, and third-party payers;
the regulatory approval pathway that we pursue for DCCR … believe such product candidates, if approved, will provide a clinical utility or benefit to patients;
whether the medical community accepts
424B5
SLNO
Soleno Therapeutics Inc
27 Sep 23
Prospectus supplement for primary offering
5:26pm
;
acceptance of DCCR, if and when approved, by patients, the medical community, and third-party payers;
the regulatory approval pathway that we … providers believe such product candidates, if approved, will provide a clinical utility or benefit to patients;
whether the medical community accepts
8-K
EX-99.1
4mxxfz5vj0nh 96m
26 Sep 23
Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from
7:30am
8-K
EX-99.1
74q ucn4gvqg9de0
10 Jul 23
Regulation FD Disclosure
4:06pm
8-K
EX-10.1
1s0 2eo7tuw9heab
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
424B5
aca2kagl
30 Mar 22
Prospectus supplement for primary offering
5:21pm
424B5
4ur19vq7csxkkdoe0rb
28 Mar 22
Prospectus supplement for primary offering
4:53pm
8-K
EX-99.1
yhv7 o0b7b3xyxsln3
5 May 21
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
4:01pm
8-K
f6atd
15 Apr 21
Other Events
12:00am
8-K
EX-99.1
wbrq8
15 Apr 21
Other Events
12:00am
8-K
EX-99.2
ucbggvobib0w8h1
15 Apr 21
Other Events
12:00am